Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 98
Filter
Add more filters










Publication year range
1.
Mol Cell ; 83(3): 393-403, 2023 02 02.
Article in English | MEDLINE | ID: mdl-36599353

ABSTRACT

The positive transcription elongation factor b (P-TEFb) is composed of cyclins T1 or T2 and cyclin-dependent kinase 9 that regulate the elongation phase of transcription by RNA polymerase II. By antagonizing negative elongation factors and phosphorylating the C-terminal domain of RNA polymerase II, P-TEFb facilitates the elongation and co-transcriptional processing of nascent transcripts. This step is critical for the expression of most eukaryotic genes. In growing cells, P-TEFb is regulated negatively by its reversible associations with HEXIM1/2 in the 7SK snRNP and positively by a number of transcription factors, as well as the super elongation complex. In resting cells, P-TEFb falls apart, and cyclin T1 is degraded by the proteasome. This complex regulation of P-TEFb has evolved for the precise temporal and spatial regulation of gene expression in the organism. Its dysregulation contributes to inflammatory and neoplastic conditions.


Subject(s)
Positive Transcriptional Elongation Factor B , RNA Polymerase II , Humans , Positive Transcriptional Elongation Factor B/genetics , Positive Transcriptional Elongation Factor B/metabolism , RNA Polymerase II/genetics , RNA Polymerase II/metabolism , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , HeLa Cells , Cyclin-Dependent Kinase 9/genetics , Cyclin-Dependent Kinase 9/metabolism , Cyclin T/genetics , Cyclin T/metabolism , Transcription, Genetic , Transcription Factors/genetics , Transcription Factors/metabolism
2.
Nucleic Acids Res ; 50(9): 5000-5013, 2022 05 20.
Article in English | MEDLINE | ID: mdl-35524561

ABSTRACT

P-TEFb, composed of CycT1 and CDK9, regulates the elongation of transcription by RNA polymerase II. In proliferating cells, it is regulated by 7SK snRNA in the 7SK snRNP complex. In resting cells, P-TEFb is absent, because CycT1 is dephosphorylated, released from CDK9 and rapidly degraded. In this study, we identified the mechanism of this degradation. We mapped the ubiquitination and degradation of free CycT1 to its N-terminal region from positions 1 to 280. This region is ubiquitinated at six lysines, where E3 ligases Siah1 and Siah2 bind and degrade these sequences. Importantly, the inhibition of Siah1/2 rescued the expression of free CycT1 in proliferating as well as resting primary cells. We conclude that Siah1/2 are the E3 ligases that bind and degrade the dissociated CycT1 in resting, terminally differentiated, anergic and/or exhausted cells.


Subject(s)
Positive Transcriptional Elongation Factor B , Transcription Factors , Ubiquitin-Protein Ligases/metabolism , Cell Physiological Phenomena , Cyclin T/genetics , Positive Transcriptional Elongation Factor B/metabolism , RNA Polymerase II/metabolism , RNA, Small Nuclear , Transcription Factors/metabolism , Transcription, Genetic
3.
Cell Rep ; 36(6): 109514, 2021 08 10.
Article in English | MEDLINE | ID: mdl-34380030

ABSTRACT

HIV-1-negative factor (Nef) protein antagonizes serine incorporator 5 (SERINC5) by redirecting this potent restriction factor to the endosomes and lysosomes for degradation. However, the precise mechanism remains unclear. Using affinity purification/mass spectrometry, we identify cyclin K (CycK) and cyclin-dependent kinase 13 (CDK13) as a Nef-associated kinase complex. CycK/CDK13 phosphorylates the serine at position 360 (S360) in SERINC5, which is required for Nef downregulation of SERINC5 from the cell surface and its counteractivity of the SERINC5 antiviral activity. To understand the role of S360 phosphorylation, we generate chimeric proteins between CD8 and SERINC5 to study their response to Nef. Nef not only downregulates but, importantly, also binds to this chimera in an S360-dependent manner. Thus, S360 phosphorylation increases interactions between Nef and SERINC5 and initiates the destruction of SERINC5 by the endocytic machinery.


Subject(s)
CDC2 Protein Kinase/metabolism , Cyclins/metabolism , HIV Infections/virology , HIV-1/pathogenicity , Membrane Proteins/metabolism , nef Gene Products, Human Immunodeficiency Virus/metabolism , Amino Acid Sequence , Down-Regulation , HEK293 Cells , HIV Infections/metabolism , Humans , Jurkat Cells , Mass Spectrometry , Membrane Proteins/chemistry , Peptides/chemistry , Peptides/metabolism , Phosphorylation , Phosphoserine/metabolism , Protein Binding , Proteomics , Recombinant Fusion Proteins/metabolism
4.
AIDS Res Hum Retroviruses ; 36(10): 800-807, 2020 10.
Article in English | MEDLINE | ID: mdl-32683901

ABSTRACT

Despite the success of antiretroviral therapy (ART), ART fails to eradicate the virus and HIV cure has remained beyond the reach of current treatments. ART targets replicating virally infected but not latently infected cells, which have limited expression of factors important for proliferation and cellular activity, including positive transcription elongation factor b (P-TEFb) and nuclear factor κB (NF-κB). Levels of the cyclin T1 (CycT1) subunit of P-TEFb are low to absent in resting T cells, and treatment with proteasome inhibitors (PIs) increases CycT1 protein levels to those of proliferating T cells. In this study, the clinically approved PI bortezomib reactivated latent HIV in latently infected primary CD4+ T cells. Bortezomib not only increased levels of CycT1 but also activated NF-κB. Strikingly, as opposed to most currently researched latency reversing agents (LRAs), bortezomib did not require a second LRA to potently reactivate latent HIV. Effects of bortezomib on resting T cells and reactivation of HIV suggest a possible direction for future attempts to diminish the viral reservoir in HIV+ individuals.


Subject(s)
HIV Infections , HIV-1 , CD4-Positive T-Lymphocytes , HIV Infections/drug therapy , Humans , Virus Activation , Virus Latency
5.
AIDS Res Hum Retroviruses ; 35(8): 710-717, 2019 08.
Article in English | MEDLINE | ID: mdl-31044597

ABSTRACT

While the roles in HIV transcription of many cyclin-dependent kinases (CDKs) have been well defined, little is known about the impact of mediator kinases (MDKs), CDK8 and CDK19, in this process. Mediator complexes containing CDK8 or CDK19 repress or activate the expression of selected genes. The aim of this study was to investigate the role of MDKs in HIV transcription. siRNA knockdown of both MDKs had no effect on HIV transcription. This result was confirmed using two MDK inhibitors, Cortistatin A (CA) and Senexin A (SnxA). Furthermore, neither CA nor SnxA inhibited viral reactivation in Jurkat cell models of HIV latency. Taken together, these results indicate that MDKs are not required for HIV transcription.


Subject(s)
Cyclin-Dependent Kinase 8/genetics , Cyclin-Dependent Kinases/genetics , HIV-1/genetics , Transcription, Genetic/genetics , Virus Activation/drug effects , Cell Line, Tumor , Cyclin-Dependent Kinase 8/antagonists & inhibitors , Cyclin-Dependent Kinase 8/metabolism , Cyclin-Dependent Kinases/antagonists & inhibitors , Cyclin-Dependent Kinases/metabolism , HIV-1/metabolism , HeLa Cells , Humans , Jurkat Cells , Polycyclic Compounds/pharmacology , RNA Interference , RNA, Small Interfering/genetics , Virus Latency/drug effects
6.
PLoS Pathog ; 14(11): e1007402, 2018 11.
Article in English | MEDLINE | ID: mdl-30395647

ABSTRACT

Transcription of HIV provirus is a key step of the viral cycle, and depends on the recruitment of the cellular positive transcription elongation factor b (P-TEFb) to the HIV promoter. The viral transactivator Tat can displace P-TEFb from the 7SK small nuclear ribonucleoprotein, where it is bound and inactivated by HEXIM1, and bring it to TAR, which allows the stalled RNA polymerase II to transition to successful transcription elongation. In this study, we designed a chimeric inhibitor of HIV transcription by combining functional domains from HEXIM1 and Tat. The chimera (HT1) potently inhibited gene expression from the HIV promoter, by competing with Tat for TAR and P-TEFb binding, while keeping the latter inactive. HT1 inhibited spreading infection as well as viral reactivation in lymphocyte T cell line models of HIV latency, with little effect on cellular transcription and metabolism. This proof-of-concept study validates an innovative approach to interfering with HIV transcription via peptide mimicry and competition for RNA-protein interactions. HT1 represents a new candidate for HIV therapy, or HIV cure via the proposed block and lock strategy.


Subject(s)
HIV Infections/therapy , HIV-1/physiology , RNA-Binding Proteins/metabolism , Recombinant Fusion Proteins/biosynthesis , Virus Replication/physiology , tat Gene Products, Human Immunodeficiency Virus/metabolism , HEK293 Cells , HIV Infections/metabolism , HIV Infections/virology , HIV Long Terminal Repeat , HIV Seropositivity , HIV-1/genetics , HIV-1/metabolism , HeLa Cells , Humans , Jurkat Cells , Proviruses/genetics , RNA Polymerase II/genetics , RNA Polymerase II/metabolism , RNA-Binding Proteins/genetics , Recombinant Fusion Proteins/genetics , Transcription Factors , Virus Latency , tat Gene Products, Human Immunodeficiency Virus/genetics
7.
PLoS One ; 13(11): e0208055, 2018.
Article in English | MEDLINE | ID: mdl-30475902

ABSTRACT

Although anti-retroviral therapies have greatly extended the lives of HIV infected individuals, current treatments are unable to completely eliminate virally infected cells. A number of latency reversing agents have been proposed for use in a "shock and kill" strategy to reactivate latent HIV, thus making it vulnerable to killing mechanisms. Procyanidin trimer C1 (PC1) is a flavonoid found in multiple plant sources including grape, apple, and cacao, which has antioxidant and anti-inflammatory properties. We determined that PC1 reactivates latent HIV in cell line and primary cell models of HIV, through activation of the MAPK pathway. Notably, PC1 reactivates latent HIV without increasing surface markers of T cell activation. Combining several therapeutics, which activate HIV transcription through different mechanisms, is the most efficient approach to clinically reactivate latent reservoirs. We utilized PC1 (MAPK agonist), kansui (PKC agonist), and JQ1 (BET bromodomain inhibitor) in a triple combination approach to reactivate latent HIV in cell line and primary cell models of HIV latency. When used in combination, low concentrations which fail to reactivate HIV as single treatments, are effective. Thus, several mechanisms, using distinct activation pathways, act together to reactivate latent HIV.


Subject(s)
Anti-HIV Agents/pharmacology , Flavonoids/pharmacology , HIV Infections/drug therapy , HIV-1/drug effects , HIV-1/physiology , Virus Latency/drug effects , Azepines/pharmacology , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/enzymology , CD4-Positive T-Lymphocytes/virology , Cell Line , Dose-Response Relationship, Drug , Drug Synergism , Drug Therapy, Combination , Enzyme Inhibitors/pharmacology , HIV Infections/enzymology , HIV Infections/virology , Humans , Jurkat Cells , Primary Cell Culture , Triazoles/pharmacology
8.
J Biol Chem ; 293(14): 4993-5004, 2018 04 06.
Article in English | MEDLINE | ID: mdl-29463681

ABSTRACT

Autoimmune regulator (AIRE) and nuclear factor-κB (NF-κB) are transcription factors (TFs) that direct the expression of individual genes and gene clusters. Bromodomain-containing protein 4 (BRD4) is an epigenetic regulator that recognizes and binds to acetylated histones. BRD4 also has been reported to promote interactions between the positive transcription elongation factor b (P-TEFb) and AIRE or P-TEFb and NF-κB subunit p65. Here, we report that AIRE and p65 bind to P-TEFb independently of BRD4. JQ1, a compound that disrupts interactions between BRD4 and acetylated proteins, does not decrease transcriptional activities of AIRE or p65. Moreover, siRNA-mediated inactivation of BRD4 alone or in combination with JQ1 had no effects on AIRE- and NF-κB-targeted genes on plasmids and in chromatin and on interactions between P-TEFb and AIRE or NF-κB. Finally, ChIP experiments revealed that recruitment of P-TEFb to AIRE or p65 to transcription complexes was independent of BRD4. We conclude that direct interactions between AIRE, NF-κB, and P-TEFb result in efficient transcription of their target genes.


Subject(s)
Nuclear Proteins/metabolism , Transcription Factor RelA/metabolism , Transcription Factors/metabolism , Transcriptional Activation , Cell Cycle Proteins , Gene Deletion , HEK293 Cells , Humans , Insulin/genetics , Nuclear Proteins/genetics , Positive Transcriptional Elongation Factor B/metabolism , Promoter Regions, Genetic , Protein Interaction Maps , RNA Interference , Transcription Factors/genetics , AIRE Protein
9.
PLoS Pathog ; 14(1): e1006830, 2018 01.
Article in English | MEDLINE | ID: mdl-29304101

ABSTRACT

The lentiviral protein Viral Infectivity Factor (Vif) counteracts the antiviral effects of host APOBEC3 (A3) proteins and contributes to persistent HIV infection. Vif targets A3 restriction factors for ubiquitination and proteasomal degradation by recruiting them to a multi-protein ubiquitin E3 ligase complex. Here, we describe a degradation-independent mechanism of Vif-mediated antagonism that was revealed through detailed structure-function studies of antibody antigen-binding fragments (Fabs) to the Vif complex. Two Fabs were found to inhibit Vif-mediated A3 neutralization through distinct mechanisms: shielding A3 from ubiquitin transfer and blocking Vif E3 assembly. Combined biochemical, cell biological and structural studies reveal that disruption of Vif E3 assembly inhibited A3 ubiquitination but was not sufficient to restore its packaging into viral particles and antiviral activity. These observations establish that Vif can neutralize A3 family members in a degradation-independent manner. Additionally, this work highlights the potential of Fabs as functional probes, and illuminates how Vif uses a multi-pronged approach involving both degradation dependent and independent mechanisms to suppress A3 innate immunity.


Subject(s)
Antiviral Agents/pharmacology , Cytosine Deaminase/metabolism , Immunoglobulin Fab Fragments/chemistry , vif Gene Products, Human Immunodeficiency Virus/immunology , APOBEC Deaminases , Antiviral Agents/chemistry , Cullin Proteins/chemistry , Cullin Proteins/metabolism , Cytidine Deaminase , HEK293 Cells , HIV Infections/immunology , HIV Infections/therapy , HIV Infections/virology , HIV-1/immunology , HIV-1/metabolism , Humans , Ubiquitin/metabolism , Ubiquitination , Virus Assembly , vif Gene Products, Human Immunodeficiency Virus/chemistry
10.
AIDS Res Hum Retroviruses ; 34(1): 31-38, 2018 01.
Article in English | MEDLINE | ID: mdl-29226706

ABSTRACT

The study of natural products in biomedical research is not a modern concept. Many of the most successful medical therapeutics are derived from natural products, including those studied in the field of HIV/AIDS. Biomedical research has a rich history of discovery based on screens of medicinal herbs and traditional medicine practices. Compounds derived from natural products, which repress HIV and those that activate latent HIV, have been reported. It is important to remember the tradition in medical research to derive therapies based on these natural products and to overcome the negative perception of natural products as an "alternative medicine."


Subject(s)
Anti-HIV Agents/pharmacology , Biological Products/pharmacology , HIV-1/drug effects , Anti-HIV Agents/chemistry , Biological Products/chemistry , HIV Infections/drug therapy , HIV-1/physiology , Humans , Plants, Medicinal/chemistry , Virus Latency/drug effects , Virus Replication/drug effects
11.
J Virol ; 91(11)2017 06 01.
Article in English | MEDLINE | ID: mdl-28331090

ABSTRACT

P-element-induced wimpy-like (Piwil) proteins restrict the replication of mobile genetic elements in the germ line. They are also expressed in many transformed cell lines. In this study, we discovered that the human Piwil 2 (Hili) protein can also inhibit HIV replication, especially in activated CD4+ T cells that are the preferred target cells for this virus in the infected host. Although resting cells did not express Hili, its expression was rapidly induced following T cell activation. In these cells and transformed cell lines, depletion of Hili increased levels of viral proteins and new viral particles. Further studies revealed that Hili binds to tRNA. Some of the tRNAs represent rare tRNA species, whose codons are overrepresented in the viral genome. Targeting tRNAArg(UCU) with an antisense oligonucleotide replicated effects of Hili and also inhibited HIV replication. Finally, Hili also inhibited the retrotransposition of the endogenous intracysternal A particle (IAP) by a similar mechanism. Thus, Hili joins a list of host proteins that inhibit the replication of HIV and other mobile genetic elements.IMPORTANCE Piwil proteins inhibit the movement of mobile genetic elements in the germ line. In their absence, sperm does not form and male mice are sterile. This inhibition is thought to occur via small Piwi-interacting RNAs (piRNAs). However, in some species and in human somatic cells, Piwil proteins bind primarily to tRNA. In this report, we demonstrate that human Piwil proteins, especially Hili, not only bind to select tRNA species, including rare tRNAs, but also inhibit HIV replication. Importantly, T cell activation induces the expression of Hili in CD4+ T cells. Since Hili also inhibited the movement of an endogenous retrovirus (IAP), our finding shed new light on this intracellular resistance to exogenous and endogenous retroviruses as well as other mobile genetic elements.


Subject(s)
Argonaute Proteins/metabolism , HIV-1/physiology , Lymphocyte Activation , Virus Replication , Argonaute Proteins/deficiency , Argonaute Proteins/genetics , Argonaute Proteins/immunology , Cell Line , Endogenous Retroviruses/metabolism , HEK293 Cells , HIV-1/genetics , HeLa Cells , Humans , Oligonucleotides, Antisense/genetics , Protein Binding , RNA, Small Interfering/metabolism , RNA, Transfer/metabolism , RNA, Transfer, Arg/genetics , RNA, Transfer, Arg/metabolism , T-Lymphocytes/virology
12.
PLoS One ; 11(12): e0168027, 2016.
Article in English | MEDLINE | ID: mdl-27977742

ABSTRACT

While highly active anti-retroviral therapy has greatly improved the lives of HIV infected individuals, these treatments are unable to eradicate the virus. Current approaches to reactivate the virus have been limited by toxicity, lack of an orally available therapy, and limited responses in primary CD4+ T cells and in clinical trials. The PKC agonist ingenol, purified from Euphorbia plants, is a potent T cell activator and reactivates latent HIV. Euphorbia kansui itself has been used for centuries in traditional Chinese medicine to treat ascites, fluid retention, and cancer. We demonstrate that an extract of this plant, Euphorbia kansui, is capable of recapitulating T cell activation induced by the purified ingenol. Indeed, Euphorbia kansui induced expression of the early T cell activation marker CD69 and P-TEFb in a dose-dependent manner. Furthermore, Euphorbia kansui reactivated latent HIV in a CD4+ T cell model of latency and in HIV+ HAART suppressed PBMC. When combined with the other latency reversing agents, the effective dose of Euphorbia kansui required to reactive HIV was reduced 10-fold and resulted in synergistic reactivation of latent HIV. We conclude that Euphorbia Euphorbia kansui reactivates latent HIV and activates CD4+ T cells. When used in combination with a latency reversing agent, the effective dose of Euphorbia kansui is reduced; which suggests its application as a combination strategy to reactivate latent HIV while limiting the toxicity due to global T cell activation. As a natural product, which has been used in traditional medicine for thousands of years, Euphorbia kansui is attractive as a potential treatment strategy, particularly in resource poor countries with limited treatment options. Further clinical testing will be required to determine its safety with current anti-retroviral therapies.


Subject(s)
Euphorbia/chemistry , HIV Infections/drug therapy , Virus Latency/drug effects , Adult , CD4-Positive T-Lymphocytes/metabolism , Cell Line , Cells, Cultured , Diterpenes/pharmacology , Diterpenes/therapeutic use , Drug Synergism , Female , Flow Cytometry , Humans , Male , Medicine, Chinese Traditional/methods , Middle Aged , Real-Time Polymerase Chain Reaction , Signal Transduction/drug effects
13.
J Biol Chem ; 291(34): 17953-63, 2016 08 19.
Article in English | MEDLINE | ID: mdl-27365398

ABSTRACT

The autoimmune regulator (AIRE) is a transcription factor which is expressed in medullary thymic epithelial cells. It directs the expression of otherwise tissue-specific antigens, which leads to the elimination of autoreactive T cells during development. AIRE is modified post-translationally by phosphorylation and ubiquitylation. In this report we connected these modifications. AIRE, which is phosphorylated on two specific residues near its N terminus, then binds to the F-box protein 3 (FBXO3) E3 ubiquitin ligase. In turn, this SCF(FBXO3) (SKP1-CUL1-F box) complex ubiquitylates AIRE, increases its binding to the positive transcription elongation factor b (P-TEFb), and potentiates its transcriptional activity. Because P-TEFb is required for the transition from initiation to elongation of transcription, this interaction ensures proper expression of AIRE-responsive tissue-specific antigens in the thymus.


Subject(s)
F-Box Proteins/metabolism , Transcription Factors/metabolism , Transcription, Genetic/physiology , Ubiquitination/physiology , Animals , F-Box Proteins/genetics , HEK293 Cells , Humans , Mice , Phosphorylation/physiology , Positive Transcriptional Elongation Factor B/genetics , Positive Transcriptional Elongation Factor B/metabolism , Protein Domains , SKP Cullin F-Box Protein Ligases/genetics , SKP Cullin F-Box Protein Ligases/metabolism , Transcription Factors/genetics , AIRE Protein
14.
Viruses ; 8(7)2016 07 07.
Article in English | MEDLINE | ID: mdl-27399760

ABSTRACT

Nef proteins from all primate Lentiviruses, including the simian immunodeficiency virus of chimpanzees (SIVcpz), increase viral progeny infectivity. However, the function of Nef involved with the increase in viral infectivity is still not completely understood. Nonetheless, until now, studies investigating the functions of Nef from SIVcpz have been conducted in the context of the HIV-1 proviruses. In an attempt to investigate the role played by Nef during the replication cycle of an SIVcpz, a Nef-defective derivative was obtained from the SIVcpzWTGab2 clone by introducing a frame shift mutation at a unique restriction site within the nef sequence. This nef-deleted clone expresses an N-terminal 74-amino acid truncated peptide of Nef and was named SIVcpz-tNef. We found that the SIVcpz-tNef does not behave as a classic nef-deleted HIV-1 or simian immunodeficiency virus of macaques SIVmac. Markedly, SIVcpz-tNef progeny from both Hek-293T and Molt producer cells were completely non-infectious. Moreover, the loss in infectivity of SIVcpz-tNef correlated with the inhibition of Gag and GagPol processing. A marked accumulation of Gag and very low levels of reverse transcriptase were detected in viral lysates. Furthermore, these observations were reproduced once the tNef peptide was expressed in trans both in SIVcpzΔNef and HIV-1WT expressing cells, demonstrating that the truncated peptide is a dominant negative for viral processing and infectivity for both SIVcpz and HIV-1. We demonstrated that the truncated Nef peptide binds to GagPol outside the protease region and by doing so probably blocks processing of both GagPol and Gag precursors at a very early stage. This study demonstrates for the first time that naturally-occurring Nef peptides can potently block lentiviral processing and infectivity.


Subject(s)
Gene Products, nef/metabolism , HIV-1/physiology , Simian Immunodeficiency Virus/physiology , Virus Replication , Animals , Cell Line , Frameshift Mutation , Gene Knockout Techniques , Gene Products, gag/metabolism , Gene Products, nef/genetics , Gene Products, pol/metabolism , Humans , Pan troglodytes , Protein Binding , Simian Immunodeficiency Virus/genetics
15.
F1000Res ; 52016.
Article in English | MEDLINE | ID: mdl-27303638

ABSTRACT

While highly active anti-retroviral therapy has greatly improved the lives of HIV-infected individuals, current treatments are unable to completely eradicate the virus. This is due to the presence of HIV latently infected cells which harbor transcriptionally silent HIV. Latent HIV does not replicate or produce viral proteins, thereby preventing efficient targeting by anti-retroviral drugs. Strategies to target the HIV latent reservoir include viral reactivation, enhancing host defense mechanisms, keeping latent HIV silent, and using gene therapy techniques to knock out or reactivate latent HIV. While research into each of these areas has yielded promising results, currently no one mechanism eradicates latent HIV. Instead, combinations of these approaches should be considered for a potential HIV functional cure.

16.
Mol Cell ; 62(1): 34-46, 2016 Apr 07.
Article in English | MEDLINE | ID: mdl-27058786

ABSTRACT

Studying cancer metabolism gives insight into tumorigenic survival mechanisms and susceptibilities. In melanoma, we identify HEXIM1, a transcription elongation regulator, as a melanoma tumor suppressor that responds to nucleotide stress. HEXIM1 expression is low in melanoma. Its overexpression in a zebrafish melanoma model suppresses cancer formation, while its inactivation accelerates tumor onset in vivo. Knockdown of HEXIM1 rescues zebrafish neural crest defects and human melanoma proliferation defects that arise from nucleotide depletion. Under nucleotide stress, HEXIM1 is induced to form an inhibitory complex with P-TEFb, the kinase that initiates transcription elongation, to inhibit elongation at tumorigenic genes. The resulting alteration in gene expression also causes anti-tumorigenic RNAs to bind to and be stabilized by HEXIM1. HEXIM1 plays an important role in inhibiting cancer cell-specific gene transcription while also facilitating anti-cancer gene expression. Our study reveals an important role for HEXIM1 in coupling nucleotide metabolism with transcriptional regulation in melanoma.


Subject(s)
Melanoma/metabolism , Positive Transcriptional Elongation Factor B/genetics , Pyrimidines/metabolism , RNA-Binding Proteins/genetics , RNA-Binding Proteins/metabolism , Animals , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Humans , Melanoma/genetics , Melanoma/pathology , Melanoma, Experimental , Oncogene Proteins/genetics , Transcription Factors , Transcription, Genetic , Tumor Suppressor Proteins/genetics , Zebrafish/genetics , Zebrafish Proteins/genetics , Zebrafish Proteins/metabolism
17.
J Clin Invest ; 126(2): 448-54, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26731470

ABSTRACT

HIV seeds reservoirs of latent proviruses in the earliest phases of infection. These reservoirs are found in many sites, including circulating cells, the lymphoid system, the brain, and other tissues. The "shock and kill" strategy, where HIV transcription is reactivated so that antiretroviral therapy and the immune system clear the infection, has been proposed as one approach to curing AIDS. In addition to many defective viruses, resting hematopoietic cells harbor transcriptionally latent HIV. Understanding basic mechanisms of HIV gene expression provides a road map for this strategy, allowing for manipulation of critical cellular and viral transcription factors in such a way as to maximize HIV gene expression while avoiding global T cell activation. These transcription factors include NF-κB and the HIV transactivator of transcription (Tat) as well as the cyclin-dependent kinases CDK13 and CDK11 and positive transcription elongation factor b (P-TEFb). Possible therapies involve agents that activate these proteins or release P-TEFb from the inactive 7SK small nuclear ribonucleoprotein (snRNP). These proposed therapies include PKC and MAPK agonists as well as histone deacetylase inhibitors (HDACis) and bromodomain and extraterminal (BET) bromodomain inhibitors (BETis), which act synergistically to reactivate HIV in latently infected cells.


Subject(s)
Gene Expression Regulation, Viral/physiology , HIV Infections/metabolism , HIV-1/physiology , Virus Latency/physiology , Animals , CDC2 Protein Kinase/genetics , CDC2 Protein Kinase/metabolism , Cyclin-Dependent Kinases/genetics , Cyclin-Dependent Kinases/metabolism , Gene Expression Regulation, Viral/drug effects , HIV Infections/drug therapy , HIV Infections/genetics , Humans , NF-kappa B/genetics , NF-kappa B/metabolism , Positive Transcriptional Elongation Factor B/genetics , Positive Transcriptional Elongation Factor B/metabolism , Ribonucleoproteins, Small Nuclear/genetics , Ribonucleoproteins, Small Nuclear/metabolism , Virus Latency/drug effects , tat Gene Products, Human Immunodeficiency Virus/genetics , tat Gene Products, Human Immunodeficiency Virus/metabolism
18.
Cell Host Microbe ; 18(5): 560-70, 2015 Nov 11.
Article in English | MEDLINE | ID: mdl-26567509

ABSTRACT

Transcriptional cyclin-dependent kinases play important roles in eukaryotic gene expression. CDK7, CDK9 (P-TEFb), and CDK13 are also critical for HIV replication. However, the function of CDK11 remained enigmatic. In this report, we determined that CDK11 regulates the cleavage and polyadenylation (CPA) of all viral transcripts. CDK11 was found associated with the TREX/THOC, which recruited this kinase to DNA. Once at the viral genome, CDK11 phosphorylated serines at position 2 in the CTD of RNAPII, which increased levels of CPA factors at the HIV 3' end. In its absence, cleavage of viral transcripts was greatly attenuated. In contrast, higher levels of CDK11 increased the length of HIV poly(A) tails and the stability of mature viral transcripts. We conclude that CDK11 plays a critical role for the cotranscriptional processing of all HIV mRNA species.


Subject(s)
Cell Cycle Proteins/metabolism , Cyclin-Dependent Kinases/genetics , Exodeoxyribonucleases/metabolism , HIV/genetics , Nuclear Proteins/metabolism , Phosphoproteins/metabolism , RNA 3' End Processing , DNA-Binding Proteins , HEK293 Cells , HeLa Cells , Humans , Jurkat Cells , Phosphorylation , Polyadenylation , RNA-Binding Proteins
19.
PLoS Pathog ; 11(7): e1005063, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26225566

ABSTRACT

The persistence of latently infected cells in patients under combinatory antiretroviral therapy (cART) is a major hurdle to HIV-1 eradication. Strategies to purge these reservoirs are needed and activation of viral gene expression in latently infected cells is one promising strategy. Bromodomain and Extraterminal (BET) bromodomain inhibitors (BETi) are compounds able to reactivate latent proviruses in a positive transcription elongation factor b (P-TEFb)-dependent manner. In this study, we tested the reactivation potential of protein kinase C (PKC) agonists (prostratin, bryostatin-1 and ingenol-B), which are known to activate NF-κB signaling pathway as well as P-TEFb, used alone or in combination with P-TEFb-releasing agents (HMBA and BETi (JQ1, I-BET, I-BET151)). Using in vitro HIV-1 post-integration latency model cell lines of T-lymphoid and myeloid lineages, we demonstrated that PKC agonists and P-TEFb-releasing agents alone acted as potent latency-reversing agents (LRAs) and that their combinations led to synergistic activation of HIV-1 expression at the viral mRNA and protein levels. Mechanistically, combined treatments led to higher activations of P-TEFb and NF-κB than the corresponding individual drug treatments. Importantly, we observed in ex vivo cultures of CD8+-depleted PBMCs from 35 cART-treated HIV-1+ aviremic patients that the percentage of reactivated cultures following combinatory bryostatin-1+JQ1 treatment was identical to the percentage observed with anti-CD3+anti-CD28 antibodies positive control stimulation. Remarkably, in ex vivo cultures of resting CD4+ T cells isolated from 15 HIV-1+ cART-treated aviremic patients, the combinations bryostatin-1+JQ1 and ingenol-B+JQ1 released infectious viruses to levels similar to that obtained with the positive control stimulation. The potent effects of these two combination treatments were already detected 24 hours post-stimulation. These results constitute the first demonstration of LRA combinations exhibiting such a potent effect and represent a proof-of-concept for the co-administration of two different types of LRAs as a potential strategy to reduce the size of the latent HIV-1 reservoirs.


Subject(s)
Bryostatins/pharmacology , CD4-Positive T-Lymphocytes/virology , Gene Expression Regulation, Viral/drug effects , HIV-1/drug effects , CD4-Positive T-Lymphocytes/drug effects , Diterpenes/metabolism , HIV-1/physiology , Humans , Positive Transcriptional Elongation Factor B/metabolism , Virus Activation/drug effects , Virus Latency/drug effects
20.
Mol Cell Biol ; 35(2): 468-78, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25384976

ABSTRACT

Transcriptional cyclin-dependent kinases (CDKs) regulate RNA polymerase II initiation and elongation as well as cotranscriptional mRNA processing. In this report, we describe an important role for CDK12 in the epidermal growth factor (EGF)-induced c-FOS proto-oncogene expression in mammalian cells. This kinase was found in the exon junction complexes (EJC) together with SR proteins and was thus recruited to RNA polymerase II. In cells depleted of CDK12 or eukaryotic translation initiation factor 4A3 (eIF4A3) from the EJC, EGF induced fewer c-FOS transcripts. In these cells, phosphorylation of serines at position 2 in the C-terminal domain (CTD) of RNA polymerase II, as well as levels of cleavage-stimulating factor 64 (Cstf64) and 73-kDa subunit of cleavage and polyadenylation specificity factor (CPSF73), was reduced at the c-FOS gene. These effects impaired 3' end processing of c-FOS transcripts. Mutant CDK12 proteins lacking their Arg-Ser-rich (RS) domain or just the RS domain alone acted as dominant negative proteins. Thus, CDK12 plays an important role in cotranscriptional processing of c-FOS transcripts.


Subject(s)
Cyclin-Dependent Kinases/metabolism , Intercellular Signaling Peptides and Proteins/metabolism , Mutation/genetics , Proto-Oncogene Proteins c-fos/metabolism , RNA Polymerase II/metabolism , RNA, Messenger/genetics , Cyclin-Dependent Kinases/genetics , Humans , Phosphorylation , Proto-Oncogene Mas , Proto-Oncogene Proteins c-fos/genetics , Transcriptional Activation/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...